anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To provide an absorbefacient for an oral drug by using an acyloxyalkanoylcholine sulfonate derivative as an active component. CONSTITUTION:The objective agent contains an acyloxyalkanoylcholine sulfonate derivative of formula (R<1> and R<2> are 1-5C lower alkyl; X is sulfonic acid residue; n is a number equal to the number of sulfonyloxy groups of sulfonic acid residue and is 1-4) as an active component. The above active component remarkably improves the absorption of an oral drug and keeps high drug concentration in blood. There is no particular restriction in the oral drug usable in the present invention provided that the drug is an ester-type prodrug having an ester group protected with a protecting group which is eliminated in a living body and preferably the drug is an ester-type prodrug beta-lactam antibiotic substance (e.g. pivmecillinam), etc. The absorbefacient is administered at an amount of 0.01-10pts.wt. per 1pt. of the oral drug in 1 - several divided doses.
Individuals with neck pain will receive a exercises program. Participants will receive treatments during 4 weeks, 1 treatments per week.
The patients start with the DOMINO diet (8 weeks). Patients that experienced no symptom improvement, will switch to the strict low FODMAP diet (6 weeks).
<P>PROBLEM TO BE SOLVED: To provide polynucleotides, as well as polypeptides encoded thereby, that are differentially expressed in breast cancer cells.  <P>SOLUTION: The polynucleotides are useful in a variety of diagnostic and therapeutic methods. The methods of reducing growth of breast cancer cells are further provided. These methods are useful for treating breast cancer cells. The method and composition, useful for detection of cancerous cells, identification of factors controlling the expression type of cancerous cells, and identification of the therapeutic target of chemotherapy of cancerous cells, are provided.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Neuroinflammation and synaptodendritic damage represent the pathological hallmarks of HIV-1 associated cognitive disorders (HAND). The post-synaptic protein neurogranin (Nrgn) is significantly reduced in the frontal cortex of postmortem brains from people with HIV (PWH) and it is associated with inflammatory factors released by infected microglia/macrophages. However, the mechanism involved in synaptic loss have yet to be elucidated. In this study, we characterized a newly identified long non-coding RNA (lncRNA) transcript (RP11-677M14.2), which is antisense to the NRGN locus and is highly expressed in the frontal cortex of HIV-1 individuals. Further analysis indicates an inverse correlation between the expression of RP11-677M14.2 RNA and Nrgn mRNA. Additionally, the Nrgn-lncRNA axis is dysregulated in neurons exposed to HIV-1 infected microglia conditioned medium enriched with IL-1β. Moreover, in vitro overexpression of this lncRNA impacts Nrgn expression at both mRNA and protein levels. Finally, we modeled the Nrgn-lncRNA dysregulation within an HIV-1-induced inflammatory environment using brain organoids, thereby corroborating our in vivo and in vitro findings. Together, our study implicates a plausible role for lncRNA RP11-677M14.2 in modulating Nrgn expression that might serve as the mechanistic link between Nrgn loss and cognitive dysfunction in HAND, thus shedding new light on the mechanisms underlying synaptodendritic damage.
This invention relates generally to compositions and methods which utilization nuclear receptors for regulating adipogenesis in cells. Specifically, the invention is directed to compositions which regulate transcription factor PPARγ .  and enhance or inhibit the transcription of genes responsible for directing cell differentiation towards a pathway of adipogenesis. More specifically, disclosed herein is a novel polypeptide coactivator of PPARγ, and fragments thereof, which possess coactivator or corepressor activity. Also related are nucleotide sequences which express these polypeptides. Also disclosed is an interfering RNA that may be used to inhibit adipogenesis.
Schizophrenia is a severe mental disorder that is marked by significant disruption in a person's thought and emotional processes, frequently involving psychotic features. Identifying behavioral changes and symptoms that indicate the beginning stages of schizophrenia is important for early intervention and prevention of a full psychotic episode. These initial symptoms, known as the prodromal symptoms of psychosis, may include odd behaviors, increased social withdrawal, difficulty concentrating, inappropriate emotional responses, suspicion of others, and dramatic sleep and appetite changes. Common treatments for adolescents demonstrating prodromal symptoms include forms of psychotherapy, nutritional training, and low doses of medication. As a form of psychotherapy, neuroadaptive cognitive training exercises delivered on a computer may be the most effective means of remediating the thinking difficulties of adolescents who are experiencing prodromal symptoms and are at risk for developing a first psychotic episode. This study will evaluate the effectiveness of intensive computerized neuroadaptive cognitive training exercises in preventing the onset of psychotic disorder and improving adaptive functioning in adolescents at high risk of schizophrenia.

Participation in this study will last 24 months and will involve both healthy participants and participants at high risk of schizophrenia. Healthy participants will only participate for 12 months. All participants will undergo baseline assessments that will include an interview, written tests, blood draws, and electroencephalogram (EEG) and magnetic resonance imaging (MRI) scans. Participants at high risk of schizophrenia will then be assigned randomly to receive treatment with either computerized neuroadaptive cognitive training or commercially available computer games. Healthy participants will receive treatment with computerized neuroadaptive cognitive training only. All participants will be asked to complete 60-minute sessions of their assigned treatments 5 days per week for 8 weeks. For participants receiving cognitive training, exercises will focus on improving speed and accuracy in the perception of and response to verbal and visuospatial targets. The treatment will focus on targeted cognitive training (TCT). Participants assigned to practice computer games will play standard, commercially available games, with no targeted response.

Participants will repeat baseline assessments at post treatment and Month 6 of follow-up. The EEG and MRI will be repeated only at the Week 8 assessment visit. There will be a blood draw at Week 2 of treatment as well. After the Month 6 assessment, healthy controls will be complete, and the at risk participants will continue to be followed up out to 24 months.
MK3207 placebo as tablets will be Orally administered to patients with water. During each period (with and without acute migraine).
PURPOSE:To obtain the subject new substance separable from a cultured product of a microbial strain belonging to the genus Streptomyces and capable of producing a melanogenesis-inhibiting substance, having excellent melanogenesis-inhibiting action, free from side effect and useful for pharmaceuticals, cosmetics, etc. CONSTITUTION:A microbial strain belonging to the genus Streptomyces and capable of producing OH-3984K1 having melanogenesis-inhibiting action [e.g. Streptomyces sp. OH-3984 (FERM P-13068)] is inoculated on a medium and cultured at 27 deg.C for 72hr under shaking to obtain a seed strain. The seed strain is transplanted to a medium in a jar fermenter and cultured under aeration and agitation. The cultured liquid is mixed with ethyl acetate, stirred and subjected to centrifugal separation to separate an extract liquid. The ethyl acetate layer is concentrated under reduced pressure, hexane is added to the residue and the hexane-insoluble fraction is subjected to chromatography to obtain the objective melanogenesis-inhibiting substance having an elemental composition of C18H26O4, a molecular weight of 306 and a specific rotation [alpha]p of -154.9 deg. (C=0.366, C2H5OH), scarcely soluble in water and soluble in acetone, ethyl ether, methanol, etc.
FIELD: veterinary science. SUBSTANCE: method involves treatment of animal distal limb parts with 1.5% Desoxon-1 solution. Treatment is carried out by immersion of limbs in bath with solution, twice, at 10-15 days interval following by running through hygroscopic lay under impregnated with slaked lime or chalk. Prophylaxis effectiveness is up to 100%. EFFECT: enhanced effectiveness of prophylaxis. 2 cl, 2 tbl
<P>PROBLEM TO BE SOLVED: To provide a new method for the site-specific chemical modification of various proteins, and to provide the resultant composition having advanced biocompatibility and bioactivity.  <P>SOLUTION: The new method comprises modifying leptin(obesity-related protein) with diethylenetriaminepentacetic acid anhydride to obtain the aimed chemically modified leptin with only the N-terminal monosuccinylated. The chemically modified leptin thus obtained has advantages in terms of bioavailability and biocompatibility. This method is also widely applicable to other proteins, e.g. a granulocyte colony stimulating factor.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Growing evidence points to a spectrum of non-motor symptoms, including cognitive difficulties that have a greater impact on functional outcomes and quality of life than motor symptoms in cervical dystonia (CD). Some cognitive impairments have been reported; however, findings are inconsistent, and described across mixed groups of dystonia. The current review aimed to examine the evidence for cognitive impairments in CD. MEDLINE, EMBASE, PsychINFO and Web of Science databases were searched. Studies were included if they met the following criteria (i) cross-sectional or longitudinal studies of adults with CD, (ii) where the results of standardised measures of cognitive or neuropsychological function in any form were assessed and reported, (iii) results compared to a control group or normative data, and (iv) were published in English. Results are presented in a narrative synthesis. Twenty studies were included. Subtle difficulties with general intellectual functioning, processing speed, verbal memory, visual memory, visuospatial function, executive function, and social cognition were identified while language, and attention and working memory appear to be relatively spared. Several methodological limitations were identified that should be considered when interpreting the evidence to describe a specific profile of cognitive impairment in CD. Clinical and research implications are discussed.
If you are breast feeding, consult your doctor before starting oral contraceptives. Some of the drug will be passed on to the child in the milk. A few adverse effects on the child have been reported, including yellowing of the skin (jaundice) and breast enlargement. In addition, oral contraceptives may decrease the amount and quality of your milk. If possible, do not use oral contraceptives and use another method of contraception while breast feeding. You should consider starting oral contraceptives only after you have weaned your child completely.
Participants with psoriasis. All participants will receive at least 3 months of treatment with adalimumab. Adalimumab was prescribed by the physician under usual and customary practice and according to the approved adalimumab New Zealand Datasheet.
Training will be performed three times a week for 12 weeks. Each session will take place on a GaitKeeper treadmill (Sammons Preston, IL) treadmill and will last 45 minutes with a 5 minute warm up and cool down of either cycling or walking.
OBJECTIVE: To investigate pathologic complete response (pCR) and recurrence outcomes using various progestin treatment strategies in patients with atypical hyperplasia/endometrial intraepithelial neoplasia (AH/EIN).
METHODS: Medical records of patients diagnosed with AH/EIN and undergoing follow-up endometrial biopsy after progestin treatment between 2011 and 2020 were retrospectively reviewed. Clinical factors and treatment outcomes were analyzed according to initial progestin treatment (oral progestin [OP], levonorgestrel-releasing intrauterine device [LNG-IUD], and combination), OP dose, and maintenance treatment using Pearson's χ2, Fisher's exact test, and Kaplan-Meier analysis.
RESULTS: Of 124 patients included, 74, 37, and 13 were in the OP, LNG-IUD, and combination groups, respectively. The pCR rate was 79.8% and recurrence rate was 21.2%. The pCR rates within 3 and 6 months were significantly higher in the OP group than in the LNG-IUD group, but were not significantly different within 12 and 24 months. Recurrence rate was significantly higher in the OP group than in the LNG-IUD group. The pCR rate and recurrence rate had no significant differences between the combination group and the other groups. Excluding the LNG-IUD group, 53 and 34 patients received low- and high-dose OP, respectively. The pCR and recurrence rates were comparable between the low- and high-dose OP groups. Maintenance therapy was significantly associated with lower recurrence rate.
CONCLUSIONS: Although OP alone achieved more short-term pCR than the other groups, more recurrences occurred after pCR than LNG-IUD alone. High-dose OP as well as combination of OP and LNG-IUD did not increase pCR or reduce recurrence. Maintenance therapy may reduce the recurrence rate after pCR.
There have been postmarketing reports of serious hypersensitivity reactions in patients treated with ONGLYZA. These reactions include anaphylaxis, angioedema, and exfoliative skin conditions. Onset of these reactions occurred within the first 3 months after initiation of treatment with ONGLYZA, with some reports occurring after the first dose. If a serious hypersensitivity reaction is suspected, discontinue ONGLYZA, assess for other potential causes for the event, and institute alternative treatment for diabetes. [See Adverse Reactions (6.2).]

Use caution in a patient with a history of angioedema to another dipeptidyl peptidase-4 (DPP4) inhibitor because it is unknown whether such patients will be predisposed to angioedema with ONGLYZA.
Temporomandibular disorder (TMD) is a multifactorial disease with complex etiopathogenesis. The main symptoms are persistent pain in the masticatory muscles and preauricular region, limitations in jaw function, and sounds in the temporomandibular joints. The most commonly used therapy is the occlusal splint (OS). The therapeutic effect of OS is attributed to various factors, however the exact mechanism is still unknown. One of the potential diagnostic methods is the use of molecular biomarkers. Studies have demonstrated a correlation between inflammatory cytokines and pain in TMD patients compared to healthy controls. Molecular biomarker levels can be determined from tissue samples and body fluids. Gingival crevicular fluid (GCF) is a serum exudate that enters the gingival sulcus from the gingival plexus of blood vessels and contains proteins, various cell types, electrolytes, cytokines, etc. Considering its composition, wide availability, non-invasive method, and speed of collection, GCF could be a new source of TMD biomarkers with potential diagnostic, prognostic, and therapeutic purposes.

Participants diagnosed with myalgia, arthralgia, headache attributed to TMP and/or painful disk displacement (with and without reduction) according to DC /TMD will be included in the study. Participants will be asked to complete self-assessment questionnaires: Graded Chronic Pain Scale (v2), Jaw Functional Limitation Scale-20, Patient Health Questionnaire-9, Genaral Anxiety Disorder-7, Patient Health Questionnaire-15, Oral Behaviors Checklist, Oral health Impact Profile, and Perceived Stress Scale-10. The occlusal splints will be fabricated from hard acrylic resin by the same dental technician in the dental laboratory. The GCF sample will be collected from the sulcus using sterile tweezers and sterile paper sticks and placed in an Eppendorf tube containing 250 µl of 0.9% NaCl solution. Blood samples will be collected in Vacutainers and stored at +4°C until centrifugation. For multicomplex quantitative analysis of proinflammatory cytokines (interleukin 1 beta (IL -1β), interleukin 6 (IL - 6), interleukin 7 (IL -7), interleukin 8 (IL -8), interleukin 13 (IL -13), tumor necrosis factor alpha (TNF-α)), adapted ProcartaPlex multiplex assays will be used.
The invention discloses a Chinese herbal preparation for treating wind yang-caused headache. The Chinese herbal preparation is characterized in that selected traditional Chinese medicinal raw materials respectively include, by weight, 10 parts of rhizoma Gastrodiae, 10 parts of uncaria laevigata, 5 parts of white peony root, 30 parts of malt, 30 parts of oyster, 9 parts of cape jasmine, 15 parts of Acorus tatarinowii Schott, 12 parts of prepared pinellia tuber, 15 parts of mulberry leaf, 15 parts of Chrysanthemum morifolium, 12 parts of Ligusticum wallichii, 6 parts of divaricate saposhnikovia root, 30 parts of black sesame and 12 parts of balloonflower root. The selected raw medicinal materials have complementary drug properties and effects. Mutual inhibition, mutual restraint and mutual-detoxication among medicines in compatibility are avoided. Mutual reinforcement and mutual-assistance among the medicines are remarkable. Thus, the Chinese herbal preparation has a function of enhancing immunity, has effects of dispelling wind, relieving pain, nourishing blood and promoting blood circulation, and is an orally-taken preparation which is prepared from pure Chinese herbal medicines and is used for treating wind yang-caused headache.
Patients will receive 5 mCi + 0.5 mCi of 89Zr-DFO-trastuzumab given IV over 5-10 min. Injection of cold trastuzumab will be mixed with 89Zr-DFO-trastuzumab so that total mass is equal to 50 mg \[1\]. In the first ten patients we wish to obtain normal organ dosimetry, pharmacokinetics \& determine optimal imaging time, therefore these patients will undergo imaging at 4 time points post injection, whole body counts \& blood draws. Subsequent patients will receive the antibody \& will only undergo imaging at a single time point (based on the first 10 patients) \& will not have whole body counts or serial bloods for pharmacokinetics. The administration of 89Zr-DFO-trastuzumab to patients undergoing a second study will be identical as for their baseline study. Patients undergoing a second injection will only have one scan that will be performed within 1 day before or 2 days after their optimum imaging time point, determined from their baseline imaging study.
PURPOSE: A Gluconacetobacter sp. gel_SEA623-2 strain is provided to ensure non-toxicity and to be applied to a mask pack and functional cosmetic product. CONSTITUTION: A novel Gluconacetobacter sp. gel_SEA623-2 strain(KACC 91526P) is used for manufacturing cellulose gel. The strain is isolated from tangerine. The pH of tangerine juice is 2.5-5.0. The strain is precultured at 25-35°C and pH 2.5-5.0. The cellulose gel has 5-20 mm of thickness and 70-95 wt% of moisture. The cellulose gel is manufactured in a cosmetic cream.
Venous thromboembolism (VTE) is a prevalent complication in cancer patients. Compared with the general population, patients with tumors are four to seven times more likely to develop venous thrombotic events. A population-based cohort study showed that the incidence of VTE in these patients has increased steadily over the past decade. Cancer-associated thrombosis may result in discontinuation of antineoplastic therapy, decreased quality of life, and increased mortality. Clinical trials indicate that prophylactic anticoagulation leads to a significantly lower rate of thrombotic disorders. However, due to the fact that thromboprophylaxis treatment increases the risk of bleeding complications and that the risk of VTE varies widely among individuals, only patients at high risk of thrombosis will benefit from primary thromboprophylaxis. In this setting, the use of anticoagulant drugs is challenging. So, the purpose of this study is to identify risk factors of cancer-associated venous thrombosis and develop a prediction model to assist clinicians in tailoring anticoagulant therapy.
A method for operating medical diagnosis data is provided to construct infrastructure for medical data by generally managing the medical data received from variously formable medical paths based on standards. Personal information is received from a patient(S100). Medical questions are transmitted to the patient and the first data, which is responded to the medial questions, is received from the patient(S120). The first data is compared with a symptom list of disease names stored in a disease name database and the first estimated diagnosis result, which is the disease name is more than a predetermined value, is output(S140). The first diagnosis information linking the personal information with the first estimated diagnosis result is stored to a database(S150). Diagnosis result information linking a diagnosis result with the personal information of the patient is received from a doctor and is stored to the database(S160). A comparison result comparing the first diagnosis information with the diagnosis result information is stored to the database(S170).
This group of subjects will follow a standard-of-care treatment regimen for AD, including the use of moisturizers and topical corticosteroids. Additionally, they will use a titanium pellet (accu-patch pellet) to self-apply pressure at the LI11 acupuncture pressure point, located on the left arm lateral to the antecubital fossae, for 10 minutes, 3 times weekly for 1 month.
Recommendations of lifestyle and dietary content changes are often made for primary prevention and improvement of many health conditions, including cardiovascular disease. For centuries, green tea (Camellia sinensis) has been linked to good health. Nowadays, it is considered a functional food because of its physiological benefits, mainly in terms of cardiovascular prevention. Green tea is considered one of the best sources of phenolic compounds, which possess antioxidant properties that may contribute to a reduction in the risk of cardiovascular disease. Lesser-known worldwide, but widely consumed in southern Latin America countries, yerba mate tea (Ilex paraguariensis) is also a good source of phenolic compounds. The antioxidant capacity of green tea has been extensively studied; however, few studies have reported that the antioxidant properties of maté tea is even greater than green tea. For this reason, the present study aims to compare the possible effects of the oral ingestion of maté and green tea on the lipid and inflammatory profiles in a southern Brazilian population.
NEW MATERIAL:The compound of formula I [R1 and R2 are H, halogen, OH, alkyl or alkoxy; R3 and R4 are H, alkyl, cycloalkyl, aralkyl or together with adjacent N atom form a ring; X is H, alkyl, aryl or carboxyl; Y is -C=O or =CH-OR5 (R5 is H, acyl or carbamoyl); A is O or S; E is O or methylene; G is alkylene; E is methylene when A is S] or its salt. EXAMPLE:Methyl 3-oxo-2-[3-(4-phenylpiperazin-1-yl)propyl]-2,3,4,5-tetrahydro-1- benzoxepine-2-carboxylate. USE:Preventive and remedy for cerebral circulation disorder. PREPARATION:The compound of formula I can be produced e.g. by subjecting the compound of formula II and the compound of formula III (W is halogen, etc.) to condensation reaction, condensation reaction followed by reduction or condensation reaction followed by reduction and acylation or carbamoylation reaction.